Article: Genaera Corporation Presents Encouraging Data on Bilateral Visual Acuity in Subjects From EVIZON Phase II Trials.

PLYMOUTH MEETING, Pa., March 29 /PRNewswire-FirstCall/ -- Genaera Corporation today presented a new subset analysis of EVIZON(TM) (squalamine lactate) clinical data at the IBC Third Annual Ocular Anti- angiogenesis Conference in Cambridge, MA, that suggests the treatment may benefit patients with wet age-related macular degeneration (AMD) whose vision has already significantly deteriorated. In an overview of Phase II clinical trial data, including recently announced 24-week interim results from Study 209 (MSI-1256F-209), Michael J. Gast, M.D., Ph.D., Senior Vice President, Clinical Research and Development, described outcomes for subjects in these studies with fellow ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!